The "History of HIV" talk I gave last week actually has this title, which I don't think is an overstatement. Posting it now with gratitude, just in time for Thanksgiving (my favorite holiday -- the gratitude and family part).
(Part 1 thread) 1/x
Must start with this 1981 @CDCMMWR report of 5 cases of PCP in Los Angeles. Have already commented on the surprising page 2 placement. There's a story behind it, right @deborahcottonmd? (Later moved to Page 1 on reprints.) Note “blue diazo” slide style
2/x
During my first year of med school, we had one lecture on AIDS, with putative causes. Not an auspicious start.
(Yes, 1983. I'm old.)
3/x
Huge breakthrough later that year with the discovery of the virus, eventually earning lead-author Françoise Barré-Sinoussi the Nobel Prize in Medicine in 2008. Specimen obtained from man with lymphadenopathy and night sweats, then cultured in lab, T-cell tropic
4/x
This is the first patient I saw during medical school with AIDS -- it was so sad. Prognosis was grim, median survival after OI was 10 months. Though he improved with experimental therapy (DHPG, later called ganciclovir), he died soon after
5/x
Big news in 1987 was approval of zidovudine (AZT) for treatment, based on this placebo-controlled study. Will never forget the mortality benefit: 19 subjects in the placebo group and 1 in the AZT group died during the study
6/x
Alas, the benefits of AZT were temporary -- due to resistance, toxicity, cost -- and a period of therapeutic nihilism started. This reached its nadir during the 1993 Berlin AIDS Conference, when the negative results from the CONCORDE study were released
7/x
HIV had became the leading cause of death among young adults as I finished my residency and started in ID, with deaths peaking in the early 1990s. For me, the striking thing about the AIDS quilt is to read ages of those who died. People in their 20s, 30s, 40s ...
8/x
Everything changed in 1996! Highlighting this study led by Trip Gulick*, as it showed sustained viral suppression with combination ART for the first time. I remember Doug Richman saying, if no replication, no resistance -- so this could last!
(*we were co-ID fellows!) 9/x
Why 1996? We now had sufficient drugs for combination therapy. Credit to Marty Hirsch (and others) for studying combination ART in vitro, demonstrating additive and sometimes synergistic activity. It worked!
10/x
The clinical benefits came rapidly -- like a bright light suddenly illuminating a dark room. Deaths from AIDS plummeted. One of my pts went to hospice in early 1996 with likely PML -- & today she is fine! Everyone cited this figure, which I like to call "the Palella-gram"
11/x
But soon after, strange side effects appeared, which initially were hidden by the dramatic benefits of treating uncontrolled HIV and restoration of immune function. All my talks on Rx in late 90s/early 2000s included this cartoon and photo collage
12/x
In addition, the regimens were so tough to take that “real world” experience fell far short of the clinical trials -- this study from Hopkins often cited. Many argued to defer ART until CD4 was < 350 -- or even 200!
13/x
Meanwhile, a global catastrophe was unfolding, esp in Sub-Saharan Africa. The HIV field was going through a tragic paradox, where PWH in rich countries wanted to stop therapy, whereas those in poor regions were desperate to start it
14/x
Tomorrow I'll finish this story and bring us up to today -- and why progress in HIV care and research truly is a "medical miracle". (I'll also post a link to the full slide set.)
Thanks for sticking around so far.
fin
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Ever submit a paper to a high-quality, high-impact factor journal and have it rejected, even though the reviews are mostly good and eminently addressable?
Certainly I have. 🙋♂️
1/x
Wouldn't it be awesome if those reviews could be used by another journal?
Peer review, after all, is a limited but critical resource in academic medicine.
Why should these reviews go to waste? And getting good peer review takes time!
2/x
That's why I'm delighted to announce that @CIDJournal -- and soon *all* the @IDSA journals -- will accept outside reviews from other high-impact journals. Some details in screen captures below. 3/x academic.oup.com/cid/pages/Manu…
... little imagining that shortly after IDWeek, this site would be embroiled in various controversies -- about which many others have already weighed in wisely!
2/x
But here's a condensed version of the talk, which explains why I'm sticking around (at least for now).
Let’s start with the (dreaded) “Learning Objectives”, which I’ve tried to enliven with pic of my pup. 3/x
Since talks on Covid get out of date as soon as you click "save", might as well post the talk given this week at @harvardmed Medical Grand Rounds, along with by @k_stephensonMD@SanjatKanjilal and Dr. Ruanne Barnabas
Here's the topic: 1/x
Let’s start with the controversy over disease severity, subject that appears both to excite and annoy people (for reasons that I hope to explain)
Also, a reminder that Omicron was a (very unwelcome) 2022 holiday "gift" -- will always link it to Thanksgiving!
2/X
These early anecdotal reports came from South Africa that the disease was milder with Omicron.
True? Or just wishful thinking? 3/X
We HIV/ID clinicians have been dealing with these for years.
Yes it's a long list, but five days will seem relatively manageable compared with chronic ritonavir administration, especially since the effect is quick on/quick off.
Some drugs on this list (e.g. statins) can be held for 5 days. Others (calcineurin inhibitors) dose-reduced and monitored. Some aren't used very often any more. There are alternatives that can be temporarily substituted in some pts (e.g. lorazepam for clonazepam).
3/x
Yesterday I posted a long thread on the extraordinary progress we’ve made in HIV care and research since report of the first cases 40 years ago. Now for Part 2!
(I stopped at around year 20. Here’s the link to Part 1, in case you want to catch up
When we left off, we'd experienced the thrill of effective combination ART. Our 2 major news magazines featured advances in HIV on their covers! One of these guys was a basketball star, the other an HIV researcher -- see if you can guess which one is which
2/x
But the excitement of having effective ART was tempered by the realization that these treatments had major issues, including side effects, high pill burdens, and low resistance barriers. The "when to start?" question became a central part of HIV care